Ovid Therapeutics Inc.
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
•OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027
Company newsroom
Ovid Therapeutics Inc.
NASDAQ:OVID
1 releases